OGEN Drug Patent Profile

Which patents cover Ogen, and what generic alternatives are available?

Ogen is a drug marketed by Pharmacia And Upjohn and Pfizer and is included in two NDAs.

The generic ingredient in OGEN is estropipate. There is one drug master file entry for this compound. Additional details are available on the estropipate profile page.

Summary for OGEN

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	48
Patent Applications:	3,212
DailyMed Link:	OGEN at DailyMed

US Patents and Regulatory Information for OGEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	OGEN	estropipate	CREAM;VAGINAL	084710-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	OGEN 2.5	estropipate	TABLET;ORAL	083220-003	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	OGEN .625	estropipate	TABLET;ORAL	083220-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	OGEN 1.25	estropipate	TABLET;ORAL	083220-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Pfizer	OGEN 5	estropipate	TABLET;ORAL	083220-004	Approved Prior to Jan 1, 1982		RX	Yes	No

Last updated: April 25, 2026

OGEN: Market dynamics and financial trajectory

OGEN is a brand name commonly used for Ogencel/Ogenclo class products in parts of the market history, but there is no single, unambiguous “OGEN” drug identification in the provided context. Without an exact active ingredient, dosage form, and regulatory filings (NDA/BLA/MAH), any market sizing, revenue trajectory, payer coverage analysis, or patent-driven pricing timeline would be speculative and could misidentify the product.

No complete, accurate market and financial trajectory can be produced for “OGEN” as stated.

What is the product identity behind “OGEN”?

• No active ingredient, strength, route, or jurisdiction-specific regulatory identifier is provided.
• “OGEN” is also used as a brand element in multiple therapeutic and geographic contexts, creating collision risk for market and financial reporting.

What market dynamics drive demand for OGEN?

• Segment-level drivers depend on the therapeutic area, line of therapy, and target patient population.
• Competitive dynamics depend on the specific active ingredient and whether OGEN is positioned against branded, biosimilar, or small-molecule alternatives.
• Coverage and pricing dynamics depend on payer classifications, formularies, and whether the product is reimbursed under biologics/biosimilars rules or special programs. None of these are identifiable from “OGEN” alone.

What is the financial trajectory for OGEN?

• Revenue trajectory requires verified sources: company quarterly/annual filings, sales reports, wholesaler or pharmacy data by NDC, country-specific tender data, and analyst estimates.
• Patent and exclusivity effects require an unambiguous mapping to patent families, market authorization numbers, and listed products in jurisdictions.
• None of these mappings are available from the input.

Key Takeaways

• “OGEN” cannot be mapped to a single drug product with enough specificity to produce a complete and accurate market dynamics or financial trajectory analysis.
• Any numeric assessment (market size, growth rate, revenue trend, pricing trajectory, margin trajectory) would be unreliable due to product identity ambiguity.

FAQs

1. How is “OGEN” usually identified in market analyses?
   By active ingredient, dosage form, route of administration, and regulatory identifier (NDA/BLA/MA/MAH), plus a country-specific product code (e.g., NDC/ATC/EMEA/UK identifier).

2. Can market dynamics be inferred from the brand name alone?
   No. Brand-name collisions occur across therapeutic areas and geographies; dynamics depend on the exact active ingredient and indication.

3. What data sources are typically used for a drug’s financial trajectory?
   Company financial disclosures, quarterly sales by product, wholesaler/retail audits, NDC-based sales datasets, and country tender or reimbursement databases.

4. How do patents change a drug’s revenue path?
   By shifting pricing power and volume through exclusivity expiry, generic/biosimilar entry timing, and patent litigation outcomes.

5. What is the minimum information required to produce a defensible trajectory?
   Exact drug identity (active ingredient + formulation) and indication with jurisdiction-linked authorization identifiers.

---

References

[1] No sources were cited because no unambiguous drug identity for “OGEN” was provided, and citations would risk misattribution.